NCT02223598 (CLC-102) is a Phase 1 clinical trial of CB-5083 in Lymphoid Hematological Malignancies, sponsored by Cleave Biosciences, Inc..

Who is sponsoring NCT02223598?

NCT02223598 is sponsored by Cleave Biosciences, Inc..

What drugs are being tested in NCT02223598?

Interventions in NCT02223598: CB-5083, Dexamethasone.

What condition does NCT02223598 study?

NCT02223598 studies Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma.

Is NCT02223598 still recruiting?

NCT02223598 is currently terminated. Last updated 27 February 2018.

Last reviewed 2018-02-27 · How we verify

NCT02223598: CLC-102

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

Terminated Phase 1 Last updated 27 February 2018

What this trial tests

Phase 1 trial testing CB-5083 in Lymphoid Hematological Malignancies in 120 participants. Terminated before completion.

Timeline

25 August 2014

Primary endpoint
26 July 2017

26 July 2017

Quick facts

Lead sponsor	Cleave Biosciences, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	25 August 2014
Primary completion	26 July 2017
Estimated completion	26 July 2017
Sites	8 locations across Canada, United States

Drugs / interventions tested

CB-5083 — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Lymphoid Hematological Malignancies — all drugs for Lymphoid Hematological Malignancies →
Relapsed and Refractory Multiple Myeloma — all drugs for Relapsed and Refractory Multiple Myeloma →

Sponsor

Cleave Biosciences, Inc.

Who can join

18 and older, any sex, with Lymphoid Hematological Malignancies or Relapsed and Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.
Bastola P, Neums L, Schoenen FJ, Chien J. · · 2016 · cited 71× · PMID 27729194 · DOI 10.1016/j.molonc.2016.09.005
Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer.
Costantini S, Capone F, Polo A, Bagnara P, et al · · 2021 · cited 62× · PMID 34576340 · DOI 10.3390/ijms221810177
Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma.
Xiong S, Chng WJ, Zhou J. · · 2021 · cited 61× · PMID 33599798 · DOI 10.1007/s00018-021-03756-3
Targeting p97 to Disrupt Protein Homeostasis in Cancer.
Vekaria PH, Home T, Weir S, Schoenen FJ, et al · · 2016 · cited 50× · PMID 27536557 · DOI 10.3389/fonc.2016.00181
A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6.
Leinonen H, Cheng C, Pitkänen M, Sander CL, et al · · 2021 · cited 43× · PMID 33931547 · DOI 10.1124/jpet.120.000486
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation.
Parzych K, Saavedra-García P, Valbuena GN, Al-Sadah HA, et al · · 2019 · cited 38× · PMID 30626938 · DOI 10.1038/s41388-018-0651-z
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.
Parzych K, Chinn TM, Chen Z, Loaiza S, et al · · 2015 · cited 30× · PMID 26720340 · DOI 10.1038/cddis.2015.373
Novel Agents in Multiple Myeloma.
Szalat R, Munshi NC. · · 2019 · cited 21× · PMID 30694859 · DOI 10.1097/ppo.0000000000000355

Verify or expand the search:

Other trials of CB-5083

Trials testing the same drug.

NCT02243917 — A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors · Phase 1 · terminated

Other recruiting trials for Lymphoid Hematological Malignancies

Currently open trials in the same condition.

NCT07472972 — Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell The · recruiting
NCT04283006 — A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies · EARLY_PHASE1 · recruiting

Other Cleave Biosciences, Inc. trials

Trials by the same sponsor.

NCT02243917 — A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02223598 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cleave Biosciences, Inc.
Last refreshed: 27 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02223598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing